AM 251 and beta-Funaltrexamine reduce fat intake in a fat-preferring strain of mouse.
This experiment aimed to examine the role of the CB1 and Opioid mu receptors on fat preference by administering the CB1 inverse agonist AM 251 (5mg/kg i.p.) and the opioid mu antagonist beta-Funaltrexamine (15mg/kg s.c.) for 4 days to fat-preferring C57BL/6 mice fed a two-choice high-fat/low-fat diet. Both drugs were found to significantly reduce total energy intake, high-fat diet intake and fat preference during treatment.
South
Timothy
T
Neurobiology Research Centre for Metabolic and Psychiatric Disorders, School of Health Sciences, University of Wollongong, Northfields Avenue, NSW 2522, Australia.
Deng
Chao
C
Huang
Xu-Feng
XF
D000704:Analysis of Variance; D000818:Animals; D002755:Choice Behavior / Q000187:drug effects; D004041:Dietary Fats / Q000008:administration & dosage*; D004435:Eating / Q000187:drug effects; D002149:Energy Intake / Q000187:drug effects; D005518:Food Preferences / Q000187:drug effects*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology*; D010641:Phenotype; D010880:Piperidines / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*
D004041:Dietary Fats; D009292:Narcotic Antagonists; D010880:Piperidines; D011720:Pyrazoles; C103505:AM 251; D009271:Naltrexone; C024524:beta-funaltrexamine